New Developments in CKD-MBD. The present state and problem of CKD-MBD treatment in Japan

Masatomo Taniguchi

Research output: Contribution to journalArticlepeer-review

Abstract

When considering the CKD-MBD treatment of our country, we should take account of clinical background, such as a high ratio of long-term hemodialysis patients, a small number of renal transplantation surgeries, etc. Furthermore, insurance systems differ from country to country and the universal public insurance system will also have some influences on medical circumstances in Japan. Re-considering the CKD-MBD treatment of Japan from these perspectives, there remain some issues to be addressed ; a choice of which phosphate binder is the best, a selection of treatment for severe secondary hyperparathyroidism, cinacalcet or surgery. The issues about native vitamin D agent and the treatment for osteoporosis in CKD patients should be also resolved. This article argues the present situation of CKD-MBD treatment and considers new issues and problems for more sophisticated CKD-MBD therapy in Japan.

Original languageEnglish (US)
Pages (from-to)1839-1844
Number of pages6
JournalClinical calcium
Volume24
Issue number12
StatePublished - Dec 1 2014

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'New Developments in CKD-MBD. The present state and problem of CKD-MBD treatment in Japan'. Together they form a unique fingerprint.

Cite this